Nilotinib Mylan (Nilotinib)

Nilotinib is a tyrosine kinase inhibitor used in the management of hematologic malignancies driven by BCR‑ABL fusion proteins.

• Chronic myeloid leukemia (CML): Reduces disease progression and improves survival in adult patients.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to remission induction and maintenance therapy.
• BCR‑ABL inhibitor‑resistant CML: Provides an alternative therapeutic option when prior TKIs are ineffective.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase by binding to its ATP‑binding site, thereby blocking downstream signaling pathways such as RAS/MAPK and PI3K/AKT that drive uncontrolled proliferation of malignant hematopoietic cells. The inhibition also affects related kinases like c‑KIT and PDGFR, contributing to its antileukemic activity. By maintaining sustained plasma concentrations, nilotinib achieves continuous kinase suppression, which is essential for durable clinical responses in targeted leukemias.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Rash: Mild to moderate skin eruptions.
• Nausea: Transient gastrointestinal discomfort.
• Diarrhea: Loose stools, often self‑limiting.
• Elevated liver enzymes: Mild increases in ALT/AST.

Serious or Rare Side Effects

• Cardiovascular events: Myocardial infarction, stroke, or peripheral arterial disease.
• Severe hepatic toxicity: Marked elevation of liver enzymes or hepatitis.
• Pancreatitis: Inflammation of the pancreas presenting with abdominal pain.
• QT interval prolongation: Potential for arrhythmias, especially with interacting drugs.

When prescribing nilotinib, clinicians should consider several precautionary measures to minimize risks.

• Cardiac assessment: Evaluate baseline cardiovascular status and monitor for ischemic events.
• Hepatic monitoring: Check liver function tests before initiation and periodically during therapy.
• Electrolyte balance: Correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce QT prolongation risk.
• Drug interactions: Review concomitant medications for CYP3A4 inhibitors or QT‑prolonging agents.
• Pregnancy and lactation: Avoid use in pregnant or breastfeeding women unless benefits outweigh risks.
• Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: e.g., ketoconazole, can markedly increase nilotinib plasma levels.
• Strong CYP3A4 inducers: e.g., rifampin, may substantially lower drug exposure.
• QT‑prolonging drugs: e.g., amiodarone, increase risk of cardiac arrhythmias.
• Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents: Proton pump inhibitors may modestly decrease nilotinib exposure; timing adjustment recommended.
• Statins metabolized by CYP3A4: e.g., simvastatin, may require dose reduction.
• Anticoagulants: Warfarin may have altered INR; monitor coagulation parameters.
• Herbal supplements: St. John’s wort can induce CYP3A4 and lower nilotinib levels.